Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1Phase 1/2 1

Status

Recruiting 3Completed 2Active not recruiting 2

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Breast 154Gastrointestinal 44CNS 10Thoracic 8Gynecologic 8Tumor-Agnostic 7Head & Neck 6Lymphoid 5Other solid neoplasm 4Genitourinary 4Plasma cell 3Other hematologic neoplasm 3Dermatologic 2Sarcoma 1

Conditions

Neoplasm Metastasis 3Neoplasms 2Neoplasms, Second Primary 1Adenocarcinoma 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 27Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Bevacizumab 18Surveys and Questionnaires 17Fluorouracil 14Oxaliplatin 13Cisplatin 13Leucovorin 12Cyclophosphamide 12Radiotherapy 11Radiosurgery 11Pemetrexed 11Capecitabine 11Irinotecan 10Gemcitabine 10Docetaxel 10Ipilimumab 9trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Trastuzumab × Tumor-Agnostic × 1 year × Clear all
NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04309578 2026-04-03

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Asan Medical Center

Phase 2 Completed
28 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Genentech, Inc.

Phase 2 Active not recruiting
720 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03199300 2025-12-11

InvestiCAT

University Medical Center Groningen

Active not recruiting
20 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

NCT01771458 2025-11-24

SHIVA

Institut Curie

Phase 2 Completed
742 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡